Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

  • In development
  • GID-TA10990
  • Expected publication date: TBC
Eflornithine has not yet received regulatory approval, so the committee meeting on 3 April 2025 will be held in private.